Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study

References

• Barkin J, Guimarães M, Jacobi G, Pushkar D, Taylor T, van Vierssen Trip OB, on behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461–6.
   PubMed Web of Science ®Google Scholar
• De Reijke TM, Klarskov P. Comparative efficacy of two α1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004;93:757–62.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Gonzales R, Ogiste J, Te AE. Combination of an α1-blocker, alfuzosin, and a PDE5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms and sexual dysfunction (abstract). Eur Urol 2006;Suppl 5(2):197.
   Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, , for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98.
   PubMed Web of Science ®Google Scholar
• Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95:1006–12.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B, The Influence of baseline parameters on change in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the combat study. Eur Urol 2009;55:461–71.
   PubMed Web of Science ®Google Scholar
• Debruyne F, Gres A, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170–80.
   PubMed Web of Science ®Google Scholar
• Bosch JLHR, Griffiths DJ, Blom JHM, Schroeder FH. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 1989;141:68–72.
   PubMed Web of Science ®Google Scholar
• Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo-controlled study. J Urol 1975;114:564–8.
   PubMed Web of Science ®Google Scholar
• McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin N Am 1990;17:661–70.
   PubMed Web of Science ®Google Scholar
• Ostri P, Swartz R, Meyhoff HH. Antiandrogen treatment of benign prostatic hyperplasia: a placebo controlled trial. Urol Res 1988;17:29–33.
   Google Scholar
• Bartsch G, McConell JD, Mahler C, Calais da Silva F, Klocker H, Richard F. Endocrine treatment of benign prostatic hyperplasia. In: Chatelain C, Denis L, Foo KT, Khoury S, M.C. Connell J, editors. Benign prostatic hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH). Health Publications, Plymbridge Distributors, Plymouth; 2001. p 423–57.
   Google Scholar
• Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235–46.
   PubMedGoogle Scholar
• Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P, on behalf of the Scandinavian Prostatic Cancer Group. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1-years. Scand J Urol Nephrol 2006;40:441–52.
   PubMed Web of Science ®Google Scholar
• Mommsen S, Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1994;28:401–4.
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Alund G. Urethral obstruction secondary to carcinoma of the prostate: response to endocrine treatment. Urology 1985;25:354–6.
   PubMed Web of Science ®Google Scholar
• Smith JA, Janknegt RA, Abbou CC, de Gery A. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. Eur Urol 1997;31 Suppl 3:25–9.
   PubMedGoogle Scholar
• Klarskov L, Mommsen S, Klarskov P, Svolgaard N. Endocrine treatment and LUTS in men with prostate cancer (abstract). Eur Urol 2006;Suppl 5:250.
   Google Scholar
• Andersson L. Design of clinical trials on prostate cancer. Urology 1997;49(Suppl 4A):39–45.
   PubMed Web of Science ®Google Scholar
• Hedlund PO, Damber J-E, Hagerman I, Haukaas S, Henriksson P, Iversen P, and the SPCG-5 Study Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42:220–9.
   PubMedGoogle Scholar
• Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J, Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995;76:451–8.
   PubMedGoogle Scholar